Nile Therapeutics (NLTX) Appoints Dr.Frank Litvack to Board Of Directors

Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients,  announced the appointment of Frank Litvack, M.D., to its Board of Directors

 Dr. Litvack is a seasoned veteran of the cardiovascular healthcare space, with over 25 years of academic and industry experience. Dr. Litvack is a Professor at the David Geffen School of Medicine, University of California, Los Angeles.


There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.

Post new comment

The content of this field is kept private and will not be shown publicly.